|Bid||0.3520 x 300|
|Ask||0.4900 x 40000|
|Day's Range||0.3626 - 0.3976|
|52 Week Range||0.3000 - 2.4800|
|PE Ratio (TTM)||-0.51|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Repros Therapeutics Inc. .
NEW YORK , July 17, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repros Therapeutics Inc. ("Repros" ...